Pfizer has already launched the production of doses of its RSV vaccine in its factories and at its partners across the globe. DADO RUVIC / REUTERS
LE FIGARO INFO – With this new vaccine against RSV (respiratory syncytial virus), the virus that causes bronchiolitis, the American giant targets both pregnant women and the elderly. He is preparing to deploy it next fall.
Pfizer is preparing to launch its bronchiolitis vaccine next fall. ” We hope to have a green light in time to be able to deploy our vaccine from the next winter season, announces Annaliesa Anderson, chief scientific officer of R&D for the vaccines division of Pfizer. We benefit from accelerated procedures in the United States and Europe. »
With this new vaccine against RSV (respiratory syncytial virus), the virus that causes bronchiolitis, the American giant targets both pregnant women and the elderly. Its vaccine for seniors could be approved by the FDA, the American health authority, from May, that for pregnant women in August. The examination of the first started last October, and of the second in December. Europe should follow in stride. Pfizer has already launched the production of the doses in its factories and at its partners across the globe.
Colossal financial stakes
Last fall showed that the needs are enormous…
This article is for subscribers only. You have 69% left to discover.
Want to read more?
Unlock all items immediately. Without engagement.
Already subscribed? Login